Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Infliximab (ATC L04AB02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2027 · 245 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab (ATC-Code nach WHO: L04AB02)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.

The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Establish non-exclusive rebate agreements for Infliximab (ATC L04AB02) for intravenous infusion
  • Supply of pharmaceutical products to AOK PLUS insured persons in Saxony and Thuringia
Afficher le résumé complet

This is an Open-House model for non-exclusive rebate agreements under §130a(8) SGB V for the drug Infliximab (ATC L04AB02) for intravenous infusion. The buyer is AOK PLUS (Saxony and Thuringia). The procedure is open to all pharmaceutical companies meeting participation requirements. No minimum purchase volumes are guaranteed; actual demand is unknown. The contract runs until 30 April 2027. The notice clarifies that this is not a public procurement under EU Directive 2014/24/EU but is published for transparency. No estimated value is provided. Submission is electronic via DTVP, with confidentiality obligations. The first submission deadline is 5 May 2025; later deadlines are provided in separate documents.

Risques

No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.

The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company within the meaning of §4(18) AMG

Eligibility

  • Must submit a declaration on exclusion grounds (§§123,124 GWB)

Administrative

  • Must submit a declaration on EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Infliximab (ATC L04AB02)

Open-House model for non-exclusive rebate agreements for the active substance Infliximab (intravenous infusion). All interested pharmaceutical companies can participate if they meet the conditions. No negotiation or exclusivity. Volume unknown.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2025 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Expired May 05, 2025

Détails de la procédure

Date de publication
24 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
189631-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30